SYRE Spyre Therapeutics
- 27.000
- -0.500-1.82%
- 27.000
- 0.0000.00%
Spyre Therapeutics News
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Jefferies, Goldman Sachs Among Managers for Spyre Offering >SYRE
Spyre Offering Expected to Close on or About November 20 >SYRE
Spyre: Underwritten Offering of 7,275,000 Shares Priced at $27.50 Each >SYRE
Express News | Spyre Therapeutics Inc Shares Down 1.2% in Late Trade at $28.33 Following Filing for Stock Offering
Spyre Therapeutics Faces Internal Control Challenges
Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants
Spyre Therapeutics | 10-Q/A: Quarterly report (Amendment)
Spyre Therapeutics | 10-K/A: Annual report (Amendment)
Express News | Spyre Therapeutics Inc - Material Weakness in Internal Control Over Financial Reporting Identified
Express News | Spyre Therapeutics Inc - Financial Statements for 2023 and Quarterly, Year-to-Date Periods Ended March 31, 2024 Should Not Be Relied Upon
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71
Baird Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $65
Spyre Therapeutics Is Maintained at Outperform by Baird
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $70
Spyre Therapeutics Shares Are Trading Lower. The Company Announced Interim Phase 1 Data From Its First-in-human Trial of SPY001.
Spyre Therapeutics Reports Promising Trial Results for SPY001
Express News | Spyre Therapeutics Inc : Wedbush Raises Target Price to $65 From $45
Express News | Spyre Therapeutics Inc - Spy001 Well Tolerated With Favorable Safety Profile
Spyre Therapeutics Announces Positive Interim Results From Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, With a Half-Life of >90 Days Supporting the...
Analysis
Price Target
No Data
No Data